Catalio Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Catalio Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9M	Buy	455,041 +23,027	+5%	+$1.61M	6.37%	4
2026 Q1	$32.1M	Buy	+432,014	New	+$31.3M	6.7%	2
2025 Q4	–	Sell	-622,729	Closed	-$32.3M	–	47
2025 Q3	$32.3M	Sell	622,729 -304,982	-33%	-$14.9M	5.98%	3
2025 Q2	$40.1M	Sell	927,711 -35,172	-4%	-$1.28M	8.4%	2
2025 Q1	$33.3M	Buy	962,883 +64,425	+7%	+$2.17M	8.1%	3
2024 Q4	$24.7M	Buy	+898,458	New	+$23.2M	5.39%	7

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Catalio Capital Management's BBIO Position: Q2 2026 in Review

Catalio Capital Management increased its BridgeBio Pharma (BBIO) stake by 5.3% in Q2 2026, buying an estimated $1.61M and bringing the position to 455,041 shares worth $33.9M. The position accounts for 6.37% of the portfolio, ranked #4.

Catalio Capital Management first reported a position in BBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $40.1M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Catalio Capital Management held 455,041 shares of BridgeBio Pharma worth $33.9M as of Q2 2026.
Catalio Capital Management bought 23,027 BridgeBio Pharma shares in Q2 2026, an estimated $1.61M.
BridgeBio Pharma made up 6.37% of Catalio Capital Management's portfolio in Q2 2026, its #4 holding.
Catalio Capital Management first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 6 quarters since.
Catalio Capital Management's BridgeBio Pharma position peaked at $40.1M in Q2 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.